HERMIONE: A randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer

  1. Miller, K.
  2. Cortes, J.
  3. Hurvitz, S.A.
  4. Krop, I.E.
  5. Tripathy, D.
  6. Verma, S.
  7. Riahi, K.
  8. Reynolds, J.G.
  9. Wickham, T.J.
  10. Molnar, I.
  11. Yardley, D.A.
Revista:
BMC Cancer

ISSN: 1471-2407

Any de publicació: 2016

Volum: 16

Número: 1

Tipus: Article

DOI: 10.1186/S12885-016-2385-Z GOOGLE SCHOLAR lock_openAccés obert editor
Font de les dades: Scopus